[A25-50] Pirtobrutinib (CLL) – Benefit assessment according to §35a Social Code Book V
Last updated 15.07.2025
Project no.:
A25-50
Commission:
Commission awarded on 10.04.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Adult patients with relapsed or refractory chronic lymphocytic leukaemia
Result of dossier assessment:
- Patients who have been previously treated with a Bruton’s tyrosine kinase inhibitor and not with a B-cell lymphoma 2 inhibitor: added benefit not proven
- Patients who have been previously treated with a Bruton’s tyrosine kinase inhibitor and a B-cell lymphoma 2 inhibitor: added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://doi.org/10.60584/A25-50
| Project no. | Title | Status |
|---|---|---|
| A25-27 | Pirtobrutinib (mantle cell lymphoma) – Benefit assessment according to §35a Social Code Book V | Commission completed |